LAG3 InhibitorChemicals ResearchUpdated on May 30, 2019 View more like this | Visit SHIRLEY, NY | Contact BOCSCI INC |
LAG-3 target drug
Therapeutic drugs targeting LAG-3 have been vigorously developed, one of the most important of which is IMP321. IMP321 enhances the immune response to tumor cells through two different mechanisms. IMP321 combined with MHC-II molecules on immature DC cells to promote the maturation of DC cells and to enhance antigen presentation. IMP321 also blocked the binding of MHC-II molecules to LAG-3 expressed by CD8+ T cells, thus removing the inhibitory effect of T cell activation.
BOC Sciences Company is pleased to provide you with high-quality LAG-3 target drug-related services. The company has the world's leading pharmaceutical and biotechnology R&D laboratory. Over the years, our experts have been working on the development of therapeutic drugs targeting LAG-3, and have achieved good results. The company sincerely looks forward to working with you hand in hand.
Therapeutic drugs targeting LAG-3 have been vigorously developed, one of the most important of which is IMP321. IMP321 enhances the immune response to tumor cells through two different mechanisms. IMP321 combined with MHC-II molecules on immature DC cells to promote the maturation of DC cells and to enhance antigen presentation. IMP321 also blocked the binding of MHC-II molecules to LAG-3 expressed by CD8+ T cells, thus removing the inhibitory effect of T cell activation.
BOC Sciences Company is pleased to provide you with high-quality LAG-3 target drug-related services. The company has the world's leading pharmaceutical and biotechnology R&D laboratory. Over the years, our experts have been working on the development of therapeutic drugs targeting LAG-3, and have achieved good results. The company sincerely looks forward to working with you hand in hand.
